

## NEWSLETTER

### CHEMICAL & PHARMACEUTICAL 16 - 22 March 2026



#### **35,000-ton Lithium Hexafluorophosphate Capacity Expected to Commence Production**

Tinci Materials disclosed in its investor relations activity record that the company's lithium hexafluorophosphate capacity construction and deployment are proceeding in an orderly manner. The originally planned 35,000-ton new lithium hexafluorophosphate capacity is currently progressing as scheduled and is expected to officially commence production in the second half of 2026. **(ChemNet Chemical Headlines)**

#### **Luxi Chemical's RMB 7.2 Billion (\$ 913 Million) Raw Material Supply Platform Project Announcement**

The Shandong Provincial Department of Ecology and Environment has released an announcement regarding the planned procurement of raw material supply platforms for the chemical industrial park of Luxi Chemical Group Co., Ltd. The equipment procurement list includes over 1,100 units (sets), most notably two 3,000-ton/day gasification furnaces, to facilitate raw material supply. **(ChemNet Chemical Headlines)**

#### **Fujian Fuduobang Launches Public Procurement of Fluorite Powder in March 2026**

Fujian Fuduobang Technology Co., Ltd. officially released a public procurement announcement for fluorite powder. According to the procurement announcement, the project is for fluorite powder. The procurement specifies strict quality indicators, requiring the fluorite powder to contain no less than 97% CaF<sub>2</sub>, no more than 1.0% CaCO<sub>3</sub>, no more than 1.5% SiO<sub>2</sub>, no more than 5 PPM of As, and no more than 0.04% total sulfur. **(ChemNet Chemical Headlines)**

#### **Shanghai impresses global biotech, pharma markets with quality growth**

Shanghai's biopharma sector is gaining global recognition through robust growth and international partnerships. In 2024, Shanghai firms accounted for \$30.7 billion (26.4 billion euro) in licensing deals, nearly one-third of China's total. The city's supportive ecosystem, talent and collaboration enable companies to expand worldwide. **(China Daily)**

#### **China approves world's 1st domestic drug for hepatitis B cure**

China has approved Pegbing, the world's first drug aimed at achieving a functional cure for hepatitis B. Developed domestically by Amoytop Biotech, the injectable treatment is designed for use with antiviral medication to enable sustained viral clearance. This approval marks a significant advancement against the disease, which affects millions globally. **(China Daily)**